European Research Council has awarded a Proof of Concept Grant to Institute of Bioengineering of Catalonia and their OrthoBots project, to study the treatment of joint diseases using nanorobots to deliver nanoparticle based therapy to synovial tissues https://t.co/JmYQ1727rf https://t.co/k5uZoSwJPo

ICYMI: Community-Acquired Pneumonia (CAP) https://t.co/geb8y2AK26 https://t.co/cB3y5vQoz1

Progress in SLE with new mRNA CAR-T cell Trial Cartesian Therapeutics, has announced their first-in-class mRNA CAR-T therapy has been given to the first SLE. patient in a Phase 2 open-label clinical trial. https://t.co/7SYNtjIn9F https://t.co/a5LJn8QLT3

Urticarial vasculitis - rare autoimmune dz w/ persistent edematous papules & plaques lasting >24 hrs, w/ systemic Sxs (joint pain, fever). Long-lasting skin lesions tend to leave a bruiselike look. Requires Bx show leukocytoclasticl vasculitis https://t.co/cFWrntrlMw https://t.co/JPkh5FVNo3

ICYMI: 2022 EULAR Recommendations on Screening & Prophylaxis for Opportunistic Infections https://t.co/eHn2o2pFFR https://t.co/8S1fzl4AaJ

MTX was tapered or D/C in 30% of RA pts w/in 2 yrs of b/tsDMARD Rx. Of 889 pts, MTX (19 mg/wk) tapered in 13.8% & D/C 16.5% (planned taper(37%); pt decision (27.2%). In 582 (66%) MTX unchanged, 4.25 increased MTX after b/tsDMARD initiation https://t.co/yc8exMbeD1 https://t.co/b3L3Fha7xU

Bimekizumab (dual-IL-17A/F inhib), may prevent uveitis in patients with axSpA. In phase 3 RCTs (MOBILE 1 & 2) double-blind period, uveitis seen in 0.6% on BKZ vs 4.6% on PBO (p=0.001). In pts w/ hx uveitis, again lower w/ BKZ (6.2/100 PYs vs 70.4/100 PYs) https://t.co/v0wMK45chz https://t.co/CVPdg1k41V

PMR - a Risk Factor for Recalcitrant Giant Cell Arteritis? Despite the clinical similarities and treatment differences between giant cell arteritis (GCA polymyalgia rheumatica (PMR), confusion exists regarding the impact of overlapping disorders. https://t.co/Slnq68YQgh https://t.co/nCYswGmlCk

Cost-Effectiveness of Biosimilars vs Leflunomide An economic evaluation of 25 099 rheumatoid arthritis patients found that treatment with biosimilar DMARDs were cost-effective compared with the conventional DMARD, leflunomide. https://t.co/lWJB1VL1CL https://t.co/lzra8suVqs

IV zoledronic acid (ZA) does not prevent future knee replacement (TKR) in symptomatic knee OA without severe joint space narrowing (JSN). In 222 Knee OA pts, after 7 yrs F/U, ZA had more TKR (39% vs 30%; HR 4.2' 1.2-14.7) https://t.co/2cGeqz2Rwu https://t.co/1UiODwQiK6

ICYMI: Can Mycophenolate be Stopped in Stable SLE? https://t.co/WJv2CajgW9 https://t.co/AU8X5bVSJQ

CHANCE-3 DBR-PCT of 8343 adults (>40yrs) w/ CVA or TIA & hsCRP ≥2 mg/L showed that colchicine (0.5mg) x 90d did not prevent (6.3% vs 6.5%; HR 0.98; 0.83 to 1.16) subsequent stroke within 90 days compared with placebo https://t.co/APiMYVkBTV https://t.co/VgFiCKfMqB